Mostrar el registro sencillo del ítem

dc.creatorLaing, Gavin D.
dc.creatorHarrison, Robert A.
dc.creatorTheakston, R. David G.
dc.creatorRenjifo, J.M.
dc.creatorNasidi, Abdulsalami
dc.creatorGutiérrez, José María
dc.creatorWarrell, David A.
dc.date.accessioned2017-02-06T19:25:45Z
dc.date.available2017-02-06T19:25:45Z
dc.date.issued2003-02
dc.identifier.citationhttp://www.bmj.com/content/326/7386/447.2es_ES
dc.identifier.issn1756-1833
dc.identifier.urihttp://hdl.handle.net/10669/29500
dc.descriptionCarta al editores_ES
dc.description.abstractIn Africa snakebites cause thousands of deaths annually and much permanent physical disability, but the supply of antivenom, the only specific treatment, is threatened by commercial pressures and privatisation. This has been caused over the past few years by the cessation of antivenom manufacture by Behringwerke in Germany, greatly reduced production by Aventis Pasteur in France, and the threat to continued production by Africa's sole remaining producer, the African Health Laboratory Service in Johannesburg.es_ES
dc.language.isoen_USes_ES
dc.sourceBMJ; Volumen 326. 2003es_ES
dc.subjectAnimalses_ES
dc.subjectAntivenomes_ES
dc.subjectAfricaes_ES
dc.subjectSnake Biteses_ES
dc.titlePolyspecific snake antivenom may help in antivenom crisises_ES
dc.typeinfo:eu-repo/semantics/otheres_ES
dc.identifier.doi10.1136/bmj.326.7386.447/a
dc.description.procedenceUCR::Investigación::Unidades de Investigación::Ciencias de la Salud::Instituto Clodomiro Picado (ICP)es_ES
dc.identifier.pmid12595392


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem